Compare Prologis Inc (PLD) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Prologis Inc vs Recursion Pharmaceuticals Inc — how do they compare? Prologis Inc trades at $129.49 (market cap $122.87B), while Recursion Pharmaceuticals Inc trades at $4.35 (market cap $2.14B). The key difference: Prologis Inc is far larger — about 57.4× Recursion Pharmaceuticals Inc's market cap, and Prologis Inc pays a 3.31% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Prologis Inc for 102 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| PLD | RXRX | |
|---|---|---|
Market Cap | $122.87B | $2.14B |
Volume | 4,222,957 | 30,789,535 |
Sector | Real Estate | Health |
52-Week High | $149.96 | $6.79 |
52-Week Low | $111.23 | $2.84 |
Typical Hold Time | 102 Days | 23 Days |
Enterprise Value | $157.61B | $1.66B |
Dividend Yield | 3.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PLD trades at $129.49, up 1.72% today, with a bearish technical signal from moving averages but strong fundamentals including a 45.79% net income margin and three consecutive quarterly earnings beats. The stock is supported by robust leasing activity and data center growth, as highlighted in recent CFO commentary (Defense World, 2026-09-21).
The outlook is positive with a consensus price target of $155.15 (59.52% buy ratings), but risks include rising debt-to-asset ratio (37.2% in 2025) and market volatility. Upside is driven by warehouse demand and data center expansion, while macroeconomic headwinds pose challenges.
RXRX trades at $4.255, down 0.35% on the day, with a bullish technical signal from moving averages. The company reported a net loss of $644.76 million in 2025 on $74.26 million revenue, with a negative net income margin of -961.97%. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI announced September 21, 2026, and pipeline progress presented at the Morgan Stanley Healthcare Conference.
The outlook remains speculative, driven by AI-powered drug discovery potential and partnership milestones, but significant execution risk persists due to heavy losses and high cash burn. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for long-term platform value against near-term financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Prologis Inc
Prologis was formed by the June 2011 merger of AMB Property and Prologis Trust. The company develops, acquires, and operates around 1 billion square feet of high-quality industrial and logistics facilities across the globe. The company also has a strategic capital business segment that has around $70 billion of third-party AUM. The company is organized into four global divisions (Americas, Europe, Asia, and other Americas) and operates as a real estate investment trust.
Read more on PLD →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
